Fund moves
5.6%Stake · was 5.6%
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 16, 2026 · Filed Oct 20, 2026
A major shareholder of Inmed Pharmaceuticals paid $1 out of pocket for Inmed Pharmaceuticals shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$1
Shares × reported transaction price
<$25K
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 16 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
25 days before results of Nov 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $6.60 on Oct 16, 2026, 115% above its 52-week low and 39% below its high, little changed over the previous 30 trading days
52-week range $3.08 (Mar 30, 2026) to $10.80 (Oct 21, 2025), 46% of the way up, from 251 adjusted closes. 30 trading days earlier: $6.65 on Sep 3, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +17.6% | −0.1% | +17.7% |
Past results only. Not a forecast.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Insider filing
Traded Nov 9 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
ADAR1 Capital Management, LLC, 10% owner's past purchases, 90 days after disclosure: 9 buys, median +2.3 pts vs S&P 500, beat it 6 of 9 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.